- Home
- TACH vs XFOR Comparison
TACH vs XFOR Comparison
Compare TACH & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$4.04
Company Overview
Basic Information| Metric | TACH | XFOR |
|---|---|---|
| Founded | 2024 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.1M | 377.3M |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TACH | XFOR |
|---|---|---|
| Price | $10.48 | $4.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 24.3K | ★ 669.6K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $39.02 | ★ N/A |
| Revenue Growth | N/A | ★ 150.00 |
| 52 Week Low | $10.10 | $2.80 |
| 52 Week High | $10.59 | $4.83 |
Technical Indicators
Market Signals| Indicator | TACH | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 50.77 |
| Support Level | $10.27 | $3.58 |
| Resistance Level | $10.51 | $4.48 |
| Average True Range (ATR) | 0.01 | 0.21 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 46.15 | 35.25 |
Price Performance
Historical Comparison TACH
XFOR
About TACH Titan Acquisition Corp. Class A Ordinary Shares
Titan Acquisition Corp is a blank check company.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.